These results are consistent with the well-established role of TP53 and BRCA1/2 alterations in high-grade serous ovarian carcinoma, while also highlighting the presence of rare potentially targetable alterations in other genes in a subset of patients. This evidence concerns the gene TP53 and ovarian serous carcinoma.